The drug is currently approved for treating heavily treatment-experienced (HTE) adults with multi-drug resistant HIV.

Stay up-to-date with the Dr. Reddy's Laboratories Stock Liveblog, your trusted source for real-time updates and thorough ...

Shares of Dr. Reddy's Laboratories Ltd. 500124 inched up 0.74% to 6,743.20 Indian rupees Thursday, on what proved to be an ...

Dr. Reddy’s and Hetero partner with Gilead Sciences to manufacture and distribute Lenacapavir for HIV treatment in LMICs.

Dr Reddy's Laboratories and Hetero sign non-exclusive, royalty-free agreements with Gilead Sciences to manufacture ...

Healthcare: Dr Reddy's Laboratories SA has completed the acquisition through the purchase of shares of Northstar Switzerland ...

Dr Reddy’s Laboratories said it has entered into a royalty-free non-exclusive voluntary licensing agreement with Gilead ...

Lenacapavir is a US Food and Drug Administration (FDA) approved medication indicated for the treatment of HIV type 1 (HIV-1) ...

Dr Reddy's Laboratories on Monday said its Switzerland-based subsidiary has completed the acquisition of Haleon plc's global ...

Dr Reddy's Laboratories has completed the acquisition of Haleon plc's global Nicotine Replacement Therapy (NRT) portfolio, ...

Welcome to the Dr. Reddy's Laboratories Stock Liveblog, your ultimate source for real-time updates and analysis of one of the ...

Dr Reddy's Laboratories and Hetero, along with other generic drug makers, enter into voluntary licensing agreements with ...